Overview Request Sample Pages Request Customization Download PDF
You are viewing: France Preimplantation Genetic Testing Market analysis

The France Preimplantation Genetic Testing Market was valued at $19.7 Million in 2025 and projected to reach to $32.5 Million by 2030, representing a compound annual growth rate of 10.5%. France's preimplantation genetic testing market is positioned for sustained growth through 2030, driven by technological advancements, increasing fertility treatment demand, and supportive healthcare policies.

France Preimplantation Genetic Testing Market (2025-2030) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

France Preimplantation Genetic Testing Market Trends and Insights

  • This 10.5% compound annual growth rate reflects France's increasing adoption of advanced reproductive technologies and heightened awareness of genetic screening benefits among fertility clinics and patients.
  • France's regulatory environment and strong healthcare infrastructure support the integration of PGT into assisted reproductive procedures, driving market expansion across major metropolitan centers and specialized fertility centers. The French market benefits from rising demand for non-invasive genetic diagnostics and growing parental preference for healthy embryo selection.
  • France's aging population and declining birth rates have intensified focus on reproductive efficiency, positioning PGT as a critical tool in fertility treatment protocols.
  • Between 2025 and 2030, France is expected to see increased investment in laboratory capabilities, expanded clinical adoption, and greater reimbursement recognition, collectively accelerating market penetration and revenue growth throughout the forecast period..

Key Market Statistics

  • CAGR (2025-2030) 10.5% CAGR
  • Market Size, 2025 ~USD 19.7 Million
  • Forecast, 2030 ~USD 32.5 Million
  • Country France

France Preimplantation Genetic Testing Market Overview

Market Valuation :

France's preimplantation genetic testing market is valued at $19.7 million in 2025, with strong growth trajectory reaching $32.5 million by 2030, representing a 10.5% CAGR aligned with global expansion rates.

Regulatory Framework :

France maintains a progressive regulatory environment supporting PGT adoption, with established guidelines from the French National Authority for Health (HAS) facilitating clinical implementation and reimbursement pathways for genetic screening procedures.

Fertility Clinic Adoption :

French fertility clinics are increasingly integrating advanced reproductive technologies, with growing patient demand for preimplantation genetic testing driving market penetration across major metropolitan centers including Paris, Lyon, and Marseille.

Patient Awareness Growth :

Heightened awareness among French patients regarding genetic screening benefits, coupled with improved access to information and counseling services, is accelerating adoption rates and market expansion in the reproductive medicine sector.

France Preimplantation Genetic Testing Market Dynamics

  • The 10.5% CAGR reflects France's commitment to reproductive medicine innovation and patient-centered care.
  • Key growth drivers include expanding fertility clinic networks, enhanced reimbursement coverage, and rising consumer awareness of genetic screening benefits.
  • The market will likely see consolidation among service providers and increased investment in laboratory infrastructure to meet growing demand across French regions..

Related Ecosystem

Advanced Genetic Sequencing

Top Technologies
  • Polymerase Chain Reaction (PCR)
  • Reagents
  • Assay Kits
  • Bioinformatics
  • Flow Cytometry
Top Companies
  • Thermo Fisher Scientific Inc.
  • Illumina, Inc.
  • Agilent Technologies, Inc.
  • Qiagen N.V.
  • Danaher Corporation

    Biotechnology

    Top Technologies
    • Reagents
    • Polymerase Chain Reaction (PCR)
    • Stem Cells
    • Assay Kits
    • Flow Cytometers
    Top Companies
    • Thermo Fisher Scientific Inc.
    • Merck KGaA
    • Danaher Corporation
    • Agilent Technologies, Inc.
    • Bio-Rad Laboratories, Inc.

      Key Takeaways

      • France's PGT market is valued at $19.7 million in 2025 and will reach $32.5 million by 2030, representing a 10.5% CAGR.
      • France's strong healthcare infrastructure and regulatory framework enable widespread adoption of preimplantation genetic testing in fertility clinics.
      • Rising parental demand for genetic screening and France's demographic challenges drive increased PGT utilization across reproductive centers.
      • France is expected to see expanded reimbursement coverage and laboratory investment, accelerating market growth through 2030.

      Preimplantation Genetic Testing Market Report Scope

      Report Metric Details
      Base Year 2025
      Fastest Growing Segment SINGLE GENE DISORDERS (Application)
      Forecast Period 2025–2030
      Growth Rate CAGR of 10.5% from 2025 to 2030
      Largest Segment PREIMPLANTATION GENETIC SCREENING (Procedure Type)
      Market Size Base Year (Billions) ~USD 0.69 (2025)
      Revenue Forecast (Billions) ~USD 1.14 (2030)
      Segments Covered Product & Service, Procedure Type, Technology, Application, Type, Type Of Cycle, End User

      France Preimplantation Genetic Testing Market Report Segmentation

      7 segment dimensions are covered across the global market.

      By Product & Service

      • Instruments
      • Reagents & Consumables
      • Software & Services

      By Procedure Type

      • Preimplantation Genetic Diagnosis
      • Preimplantation Genetic Screening

      By Technology

      • Comparative Genomic Hybridization
      • Fluorescence In Situ Hybridization
      • Next-Generation Sequencing
      • Polymerase Chain Reaction
      • Single-Nucleotide Polymorphism

      By Application

      • Aneuploidy
      • Gender Identification
      • Hla Typing
      • Single Gene Disorders
      • Structural Chromosomal Abnormalities
      • X-Linked Disorders

      By Type

      • Deletions
      • Duplications
      • Inversions
      • Translocations

      By Type Of Cycle

      • Fresh Donor
      • Fresh Non-Donor
      • Frozen Donor
      • Frozen Non-Donor

      By End User

      • Diagnostic Laboratories
      • Fertility Clinics
      • Hospitals
      • Other End Users

      FRANCE: PREIMPLANTATION GENETIC TESTING MARKET, BY END USER, 2023–2030

      Segment20232024202520262027202820292030CAGR (%)
      DIAGNOSTIC LABORATORIES5.15.566.77.48.29.110.210.9
      FERTILITY CLINICS14.715.817.118.720.622.725.227.910.3
      HOSPITALS3.73.94.24.655.466.59.3
      OTHER END USERS1.51.61.71.81.92.12.32.58.6
      TOTAL2526.82931.734.838.442.547.210.2

      Target Audience

      • Fertility Clinic Operators : French fertility clinics require market data to evaluate PGT service expansion, benchmark against competitors, and justify investment in genetic testing infrastructure and staff training.
      • Diagnostic Laboratory Providers : Genetic testing laboratories need France-specific market intelligence to assess demand, identify growth regions, and develop service offerings aligned with French regulatory standards and reimbursement models.
      • Medical Device & Technology Companies : Equipment manufacturers and software providers targeting French reproductive medicine need market sizing and adoption trends to prioritize product development and sales resource allocation.
      • Healthcare Investors & PE Firms : Investment professionals evaluating opportunities in French reproductive healthcare require detailed market analysis, growth projections, and competitive dynamics to support investment decisions.
      • Healthcare Policy & Regulatory Bodies : French health authorities and policy makers need market data to inform reimbursement decisions, regulatory frameworks, and healthcare resource planning for genetic testing services.

      Key Companies in the France Preimplantation Genetic Testing Market

      CompanyHQOwnershipStrongest segments
      CIMARON LABELPressure-sensitive paper labels,Film and durable labels,Specialty/custom applications,
      THERMO FISHER SCIENTIFIC INC.United StatesPublic CompanyLaboratory Products and Biopharma Services,Life Sciences Solutions,Analytical Instruments,
      AGILENT TECHNOLOGIES, INC.United StatesPublic CompanyLife Sciences and Diagnostics Markets,Agilent CrossLab,Applied Markets,
      REVVITYUnited StatesPublic CompanyReagents, Assays, and Consumables,Instruments and Detection/Imaging Platforms,Software, Subscriptions, and Informatics,
      COOPERCOMPANIESUnited StatesPublic CompanySpherical contact lenses,Toric and multifocal contact lenses,Fertility consumables, equipment, and services,
      ABBOTTUnited StatesPublic CompanyDiagnostic Products,Medical Devices,Nutritional Products,
      TAKARA BIO INC.JapanPrivate CompanyResearch reagents for genetic and cellular research,Instruments (PCR instruments and cellular analysis devices),In vitro diagnostics (including COVID-19 testing),
      VITROLIFESwedenPublic CompanyIVF media and oil,Labware (dishes, pipettes, tubes, VitroTemp, eWitness-related consumables),Cryopreservation solutions,

      CIMARON LABEL

      Insufficient information provided to generate description.

      THERMO FISHER SCIENTIFIC INC.

      Thermo Fisher Scientific Inc. is a United States-based public company founded in 1956 with 125,000 employees. The company is a global leader in serving science, providing laboratory equipment, reagents, and analytical instruments.

      AGILENT TECHNOLOGIES, INC.

      Agilent Technologies, Inc. is a United States-based public company founded in 1999 with 18,000 employees. The company provides life sciences, diagnostics, and applied chemical markets with instruments and software.

      REVVITY

      Revvity is a United States-based public company founded in 1937 with 11,000 employees. The company provides analytical technologies and solutions for research, diagnostics, and applied markets.

      COOPERCOMPANIES

      CooperCompanies is a United States-based public company founded in 1958 with 15,000 employees. The company operates in the medical device sector, primarily focused on contact lenses and eye care products.

      ABBOTT

      Abbott is a United States-based public company founded in 1888 with 115,000 employees. The company is a diversified healthcare manufacturer producing pharmaceuticals, diagnostics, nutritional products, and medical devices.

      TAKARA BIO INC.

      Takara Bio Inc. is a Japan-based private company founded in 2002 with 1,779 employees. The company specializes in biotechnology research and development.

      VITROLIFE

      Vitrolife is a Sweden-based public company founded in 1989 with 1,103 employees. The company develops and manufactures products for assisted reproduction and embryo culture.

      Reasons to Buy this Report

      • Market-Specific Sizing Data : Access precise valuation metrics for France's PGT market with 2025-2030 forecasts, enabling accurate budget allocation and revenue projections tailored to the French healthcare landscape.
      • Regulatory Intelligence : Gain insights into France's unique regulatory environment, reimbursement policies, and compliance requirements essential for market entry and operational planning in the French fertility sector.
      • Competitive Landscape Analysis : Understand the competitive positioning of fertility clinics, diagnostic laboratories, and technology providers operating in France's PGT market to identify partnership and investment opportunities.
      • Growth Driver Identification : Discover key catalysts driving France's 10.5% CAGR including patient demographics, clinic expansion plans, and technological adoption rates specific to the French market.
      • Strategic Market Entry : Develop informed go-to-market strategies for France with localized insights on patient preferences, healthcare provider networks, and regional demand variations across French territories.

      Frequently asked questions

      What is the current market size of preimplantation genetic testing in France?

      France's preimplantation genetic testing market was valued at $19.7 million in 2025 and is projected to grow to $32.5 million by 2030.

      What is the expected growth rate for France's PGT market?

      France's PGT market is expected to grow at a compound annual growth rate (CAGR) of 10.5% from 2025 to 2030.

      What factors are driving growth in France's preimplantation genetic testing market?

      Key drivers include rising parental demand for genetic screening, France's aging population, declining birth rates, improved healthcare infrastructure, and expanding reimbursement recognition for PGT procedures.

      How does France's regulatory environment support PGT adoption?

      France's strong healthcare infrastructure and supportive regulatory framework facilitate the integration of preimplantation genetic testing into assisted reproductive procedures across fertility clinics and specialized centers.

      Which regions in France are experiencing the highest PGT adoption?

      Major metropolitan centers and specialized fertility centers in France are leading PGT adoption, with expansion expected throughout the country by 2030.

      RESEARCH METHODOLOGY

      This research extensively used secondary sources, directories, and databases to gather valuable information for analyzing the global preimplantation genetic testing market. In-depth interviews were conducted with various primary respondents, including key industry players, subject-matter experts (SMEs), C-level executives, and industry consultants, to obtain and verify important qualitative and quantitative data and evaluate the market’s growth prospects. The global market size estimated through secondary research was cross-checked with inputs from primary research to determine the final market size.

      Secondary Research

      Secondary research was mainly used to gather information for the detailed technical, market, and commercial analysis of the preimplantation genetic testing market. The secondary sources for this study include the World Health Organization (WHO), World Bank, Human Fertilization and Embryology Authority (HFEA), International Federation of Fertility Societies (IFFS), American Society for Reproductive Medicine (ASRM), Australia and New Zealand Assisted Reproduction Database (ANZARD), Centers for Disease Control and Prevention (CDC), Society for Assisted Reproductive Technology (SART), National Health Service (NHS), Indian Fertility Society (IFS), British Fertility Society (BFS), European Society of Human Reproduction and Embryology (ESHRE), Association for Fertility and Reproductive Health (AFRH), German Society of Reproductive Medicine (DGRM), Canadian Fertility & Andrology Society (CFAS), Indian Society for the Study of Reproduction and Fertility (ISSRF), Spanish Fertility Society (Sociedad Española de Fertilidad-SEF), Japan Society for Reproductive Medicine, National Registry of Assisted Reproductive Technology and Surrogacy Registry, Journal of Human Reproductive Sciences, American Congress of Obstetricians and Gynecologists (ACOG), European Society of Human Genetics (ESHG); ACS Journals; corporate filings such as annual reports, SEC filings, investor presentations, and financial statements; research journals; press releases; and trade, business, and professional associations.

      Secondary data was collected and analyzed to determine the overall size of the global preimplantation genetic testing market, which was then validated through primary research. These sources also provided key information about major players, market classification, and segmentation based on industry trends, regional and country-level markets, market developments, and technological perspectives.

      Primary Research

      In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative & quantitative information and assess the market’s prospects. Various primary sources from the supply & demand sides of the market were interviewed to obtain qualitative and quantitative information.

      Preimplantation Genetic Testing Market

      To know about the assumptions considered for the study, download the pdf brochure

      Market Size Estimation

      The top-down and bottom-up approaches were used to estimate & validate the total size of the preimplantation genetic testing market. These methods were also used extensively to estimate the size of various market segments.

      Preimplantation Genetic Testing Market

      Data Triangulation

      After evaluating the overall market size through the market size estimation process, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were used, whenever applicable, to complete the overall market engineering process and obtain precise statistics for all segments and subsegments. The data was triangulated by analyzing various factors and trends from the demand and supply sides.

      Market Definition

      Preimplantation genetic testing (PGT) examines embryos during in vitro fertilization (IVF) before possible transfer to a woman's uterus. This is done to test a range of genetic problems that can cause implantation failure, miscarriage, and birth defects in a resulting child.

      Preimplantation genetic testing refers to the three types of tests that may be performed on embryos during IVF:

      • Preimplantation genetic screening for abnormal chromosome number (PGT-A)
      • Preimplantation genetic testing for monogenic (individual) disease (PGT-M)
      • Preimplantation genetic testing structural rearrangement (PGT-SR) for known chromosomal misarrangements such as inversion and translocation.

      The study offers an in-depth analysis of the preimplantation genetic testing market, examining contemporary market trends and developments, as well as its potential growth from 2025 to 2030. It includes detailed market trends, the competitive landscape, market size, forecasts, and the analysis of the key preimplantation genetic testing product and service providers.

      Stakeholders

      • Contract research organizations (CROs)
      • Contract development and manufacturing organizations (CDMOs)
      • In vitro fertilization (IVF) centers and fertility clinics
      • Life science companies
      • Fertility clinics
      • Academic & research institutes
      • Private research institutes
      • Venture capitalists & investors
      • Market research & consulting firms
      • Government associations
      • Medical institutions & universities
      • Hospitals & clinics

      Report Objectives

      • To define, describe, and forecast the preimplantation genetic testing market based on procedure type, technology, product & service, application, type of cycle, end user, and region
      • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
      • To strategically analyze micromarkets concerning individual growth trends, prospects, and contributions to the overall preimplantation genetic testing market
      • To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
      • To forecast the size of the market segments concerning six main regions, namely, North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
      • To strategically profile the key players in the preimplantation genetic testing market and comprehensively analyze their core competencies and market rankings
      • To track and analyze competitive developments such as product launches, acquisitions, expansions, agreements, partnerships, and collaborations in the preimplantation genetic testing market
      • To benchmark players within the preimplantation genetic testing market using the ‘Company Evaluation Matrix' framework, which analyzes market players based on various parameters within the broad categories of business and product strategy

      Get the Full Preimplantation Genetic Testing Market Report

      Full forecast, segment splits, and company analysis for all Preimplantation Genetic Testing Market.

      Download Sample Pages Buy Report

      METHODOLOGY

      Need a Tailored Report?

      Customize this report to your needs

      Get 10% FREE Customization

      Customize This Report
      Fact checked
      Cite this Research
      DMCA.com Protection Status